INTRODUCTION
Cardiovascular disease (CYO) is the leading cause of death in the US, the major contributor being coronary artery disease brought on by the onset of Atherosclerosis. 4 Atherosclerosis is the pathology behind the two major components of cardiovascular disease; vascular disease leading to stroke, and coronary artery disease leading to heart attacks. The main characteristic of an atherosclerotic lesion is the deposition of cholesterol in medium to large arteries. In these critical vessels, the cholesterol deposits can grow over time, until the blood now is hindered by the resulting occluded lumen, and heart attack and stroke result when the flow is completely blocked. Usually an actual rupture of a mature atherosclerotic plaque is the cause of sudden-onset heart attack or stroke. 5 One of the most important factors influencing the development of atherosclerosis is the amount of cholesterol in circulation. This relationship between cholesterol and the development of atherosclerosis was recognized early on due to the genetic disorder Familial hypercholesterolemia. Heterozygote patients with this trait have a reduced number of LDL (low density lipoprotein -a common form of cholesterol packaged for transport in the bloodstream) receptors, and homozygous individuals have no LDL receptors. This is devastating particularly in the case of hepatic cells, which are responsible for removing cholesterol from the bloodstream. Thus, these individuals have high levels of circulating cholesterol, and correspondingly short lifespan, due to earlyonset atherosclerosis and subsequent cardiovascular disease. Furthermore, cholesterollowering therapy has been found to greatly alleviate, and in some cases reverse the progression of atherosclerosis. Key among these are the statins -a group of compounds targeting the key regulatory enzyme in cholesterol synthesis: HMG-CoA reductase. 6 
The Anatomy of a Blood Vessel
Before we begin our discussion of the features and development of atherosclerotic lesions, it will help to describe the basic features of a normal artery. 
The Development of Atherosclerotic Lesions
Despite the fact that the relationship between cholesterol in circulation, cholesterol deposits in arteries and atherosclerosis is well known, the fundamental genesis of these deposits has not been definitively identified. What is known for certain is that fatty streaks -small deposits of cholesterol in the intima -begin forming at an early age in the arteries of most denizens of developed societies. Preceding the appearance of these fatty streaks, is a thickening of the intima -termed type I lesions, these instances of thickening are thought to be an adaptive response to shear stresses along the vessel wall and to tensile stresses against the wall. They are denoted as areas of eccentric thickening, as opposed to uniform thickening of the intima, called diffuse thickening, which does not directly correlate with atherosclerosis. While atherosclerotic lesions form at these sites, such areas of eccentric thickening occur whether or not atherosclerosis is present. The same stresses that result in eccentric thickening due to irregularities in the fluid flow also apparently contribute to cholesterol deposition in the intima, if serum cholesterol levels are high enough.
Thus lesions form earlier at these locations than elsewhere in the arteries, and they are therefore associated with the initial appearance of fatty streaks, and subsequently the classic locations of advanced lesions. TyPll N ( lhe.I'QfTRI.) Proteins, HDL and LDL, along with most plasma constituents, deposit within the intima throughout the arteries in proportion to their concentrations in the bloodstream and their molecular weights. In regions of eccentric thickening, however, macrophages, LDL, and the other plasma components are more concentrated. Since the endothelial layer directly adjacent to the arterial lumen is very amenable to such deposition, and since a large contributor seems to be the natural fluid flow in the lumen, it naturally follows that areas which thicken in response to excess tensile stress will accumulate additional material as a result of such stress. Thus, in these areas of eccentric thickening in normal healthy arteries the seeds of atherosclerosis are sown. The essential players are there -excess cholesterol in the form of LDL and macrophages to take them up and form foam cells.
The current predominant view is that accumulation ofLDL leads to inflammation, thus initiating the onset of atherosclerosis. 8 The oxidization of LDL and the subsequent involvement of inflammation and macrophages in foam cell formation are key factors determining whether a fatty streak will remain benign, or develop into more advanced types of atherosclerotic lesions. Such oxidization can be the target for a variety of different interventions, which will be discussed below.
Type II lesions are characterized by the formation of fatty streaks made up of macrophages that have taken up excessive amounts of lipids (foam cells). Fatty streaks are not inherently pathologic, and may never tum into type III lesions, or they may even regress on their own. In fact, each of the six types of lesions represent inherently stable entities which may remain unchanged for long periods of time, or may continue on to become more advanced lesions. 9 In the event that the fatty streaks continue to grow due to the accumulation of foam cells, type III lesions become evident. These are characterized by the appearance of extracellular lipid patches, which are the result of macrophage necrosis, and can readily accumulate by the age of 10 years. By the mid 30's they can account for one third of the surface area of the aorta. 10 Type IV lesions are considered full atheromas, conisisting of a large, contiguous 
Detoxification of Oxidized Lipids to Treat Atherosclerosis
Since oxidation of LDL has been found to be quite deleterious and inherently foundational in the etiology of atherosclerosis, the search for effective methods to detoxify this substance has been and continues to be a major field of study.23
Current Therapies Using Antioxidants and Reducing Agents
Vitamin E has been one of the most thoroughly investigated antioxidant therapies for atherosclerosis. While a number of small clinical trials have shown promising results, all large-scale clinical trials have shown no beneficial effect of vitamin E in the treatment of heart disease. 24 In several animal models, and in certain special conditions, such as 12/15-lypoxygenase gene inhibition, vitamin E has been shown to be quite beneficial in this regard. 25 It seems that in certain groups, for instance those in which oxidative stress is a system-wide pathology, such antioxidant administration can be quite beneficial.
Overall, vitamin E has been proven to be anti-oxidant or pro-oxidant or even neutral in atherogenesis, depending on myriad other factors. 26
Other antioxidants which have been assayed for therapeutic intervention in atherogenesis include Glutathione 27 , Probucol and several analogs, individual polyphenols and mixtures of polyphenols, and combination therapy using vitamin E in conjunction with Selenium, vitamin A, or vitamin C. 23 The role of human alto-ketoreductase in protection against toxic aldehydes has also been examined,28 with an eye towards potential therapies involving similar adehyde reduction. Several types of aldehyde groups resulting from lipid peroxidation have been lumped together into the category of reactive carbonyl species (RCS). These include a,p-unsaturated aldehydes, di-aldehydes, and keto-aldehydes. Since RCS are widely prevalent in atherosclerotic lesions despite the presence of large amounts of antioxidants such as vitamins C and E in the vessel wall, an alternative strategy has been developed to detoxify them -namely, the use of agents which sequester and thus nullify carbonyls directly.29 These sacrificial nucleophiles directly attack and quench aldehyde groups, rendering RCS unable to damage other biomolecules. 30 ,31 One particularly promising subset of these aldehyde quenching agents includes compounds containing a reactive thiol group. Examples include N-acetyl cysteine (NAC) and several analogs,32 as well as other compounds containing cysteine such as s-allyl cysteine, s-ethyl cysteine, s-methyl cysteine, and s-propyl cysteine. 33 Also worthy of note, are combination therapies involving thiol-containing compounds, such as the combination ofN-acetyl cysteine and taurine,34 Of particular interest is the thiol- Proposed Mechanism MPG has been found to be a very effective free radical scavenger, and also iron chelation and glutathione sparing have also been proposed as mechanisms behind the protective effects conferred by MPG. 43 The susceptibility of its reactive sulfhydril group, which is readily oxidized, makes it suited to a number of applications in ameliorating oxidative damage. In particular, such thiol-containing small molecules, such as D-Penicillamine, have been demonstrated to be highly effective quenchers of reactive aldehydes. Thus, the mechanism we propose as being most highly applicable to detoxification of atherosclerotic plaques is that of aldehyde quenching, whereby its sulfhydril group reacts directly with the aldehyde, forming thiazolidine derivatives which are nonreactive.
Experimental Approach
To test the efficacy ofMPG as a protective agent, we have used the following experimental model: Soft plaques obtained from carotid atheroma lesions are isolated and homogenized in ethanol. Murine-derived 1774 macrophage-like cells, which have been shown to respond to toxicity of atherosclerotic plaques 44 -46 , are exposed to varying concentrations of this homogenate, both with and without the addition of MPG. Standard culture viability assays are then used to determine the degree of protection conferred against plaque-induced cell death.
METHODS
Plaque Homogenization -Type I Homogenate Samples of waste from percutaneous atherectomy procedures were obtained (IRB #286.07) from Dr. Timothy Godshall, MD at University Hospital in Louisville, KY.
These were very dilute suspensions of atheroma lesion components suspended in saline.
The saline suspensions were centrifuged at 20,000g for 30 minutes. The pellet was then weighed, suspended in 2ml 100% ethanol, and homogenized in a Wheaton glass-on-glass homogenizer. After one hour of homogenization, the plaque suspension was decanted off, and the remaining non-homogenizable components were weighed and then discarded.
The suspension was further homogenized using the tightest-fitting rod for the homogenizer. After several hours of homogenization, the resulting suspension was added to additional ethanol to make a IOmg/ml stock suspension.
Plaque Homogenization -Type II Homogenate Atheromatous plaque samples from carotid endarterectomy surgical waste were obtained immediately following procedures performed by Dr. Timothy Godshall, MD at University Hospital in Louisville, KY. The entire atheroma that had been removed in the endarterectomy was weighed after minimal drying to obtain the wet weight. This intact piece was placed in a glass-on-glass Wheaton homogenizer along with I-2ml of 100%
ethanol, depending on the size of the atheroma. After one hour of homenization, the plaque suspension was decanted off, and the remaining non-homogenizable components were weighed and then discarded. The suspension was further homogenized using the tightest-fitting rod for the homogenizer. After several hours of homogenization, the resulting suspension was added to additional ethanol to make a 5 to 100mg/ml stock suspension, depending on how much material was isolated.
Plaque Homogenization -Type 111 Homogenate
In an effort to isolate more gelatinous plaque from the carotid endarterectomy surgical waste samples without exposing other components to homogenization, the gelatinous plaque components were scraped off using a scalpel. The isolated material was then weighed and homomogenized as before, except no decanting/removal of nonhomogenizable material was necessary. We also attempted to maximize the concentration of our stock solutions, giving between 75 and 100mg/ml, depending on how m much material was isolated. then stained with Gentian Violet stain for 30 minutes, rinsed with tap water, and allowed to air dry for 3 hours. Plates were then filled with powdered sugar to provide clean reads and scanned on an HP flatbed scanner. Colonies were then counted in Adobe Photos hop software, using the pencil tool with a 50pixel contrasting yellow circle to mark each colony (Figure 7 ), which ensured accuracy in counting and provided a consistent threshold for colony size.
Cell

RESULTS
In order to verify plaque toxicity in our hands, a type I plaque homogenate (see Methods section above for details) was made from dilute plaque gruel samples (see Figure 8 ). The resulting homogenate was estimated to be 10mg/ml gruel, and 0.5% of this added to test wells of a 24-well plate, giving a 50llg/ml final plaque concentration. Mostly due to the fact that the plate was too overgrown by the time the read was taken, not much toxicity could be seen, even with our lOOIlM H 2 0 2 positive control. To address these issues, the next assay ( Figure 9 ) was done using a 25% seeding density and more concentrated hydrogen peroxide, to be sure the positive control was showing up. This resulted in significant vehicle toxicity appearing from the ethanol, and virtual complete cell killing from the 1mM hydrogen peroxide. MPG and hydrogen peroxide toxicity assays (Figures 11 and 12) were done in order to find the appropriate levels for our model. In the case of MPG, we were looking for minimal toxicity. A 96-well plate was seeded at 10% confluence and allowed to incubate for 24h, at which point it was approximately 20% confluent. MPG was added in various concentrations, ranging from 5mM to 150mM Due to earlier problems in finding the appropriate H 2 0 2 concentration for use as a positive control, an H 2 0 2 toxicity assay was performed ( Figure 12 ). H 2 0 2 was added to 25% confluent 24-well plates in pre-diluted aliquots so 101-1.1 could be added to each well (wells contained 1001-1.1 medium), 101-1.1 water was added as a vehicle control to detect possible effects from medium dilution. 24-well plates were used instead of 96-well so that H 20 2 could be pipetted directly into each well, to avoid earlier problems with depletion when using basins and a multichannel pipettor for the 96-well plates. Building on the experience gleaned from the previous assays, a larger scale
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-e 100 c: experiment was done to test MPG alleviation of plaque toxicity using 6 96-well plates as replicates. Each plate contained a complete set of assays, with 4 wells being allotted to each condition ( Figure 13 ). Fresh type II plaque homogenates were used (see Methods section above for details), and plates were seeded at 20% confluence. Unfortunately this still was not enough time, over the course of a 60+ hour experiment, to prevent the wells from becoming overgrown. Thus results were once again rather obfuscated. Despite these setbacks, due to the high number of replications a somewhat consistent trend could be seen where evident toxicity at lower plaque concentrations was alleviated by the addition ofMPG. Higher plaque concentrations proved inexplicably stimulatory to a certain degree, but MPG rescue, and even stimulation in the case of controls, could be seen across the board.
In order to see more toxicity, (Figure 14) , 96-well plates were seeded at 25%
confluence, but a shorter overall time interval was used for the experiment. Three replicate plates were done, and plaque concentrations ranged from 25-1001lg/ml. 200llM nature of the experiment (under 48h from seeding to read) was intended to alleviate that problem.
The subsequent experiment ( Figure 15 ) was done using an even lower seeding were seeded at 5% confluence, grown for 24 hours and exposed to toxins for 48 hours .
MPG Decreases Plaque Toxicity
Despite the fact that toxicity was clearly evident, even in the vehicle group, MPG still apparently had no protective effect under this scenario. In fact, it seemed harmful, probably considering the smaller number of cells while MPG concentration remained at
SmM .
In order to strike a happy middle ground between too confluent and not confluent enough, we next seeded 3 96-well plates at 10% confluence, with a strict 24h regimen between seeding, adding toxins, and taking the reading (Figure 16 ). Another factor was new type III plaque homogenate (see Methods section above) . Unfortunately, the carotid endarterectomy samples made available at the time were particularly devoid of soft plaque components. Thus the samples extracted were extremely contaminated with material from the vessel wall due to excessive scraping. Thus, the Img/ml plaque concentration seems particularly intensive, yet actually reflects little plaque material.
The apparent stimulatory effects in plate 1 are more than likely due to an abnormally low control group, due to problems with seeding density.
In order to see why we were not getting hardly any plaque toxicity with the new samples, we performed two final assays Gentia n Violet stai n for30 minutes. Plates were then scanned on an HP fl atbed sca nner. Colonies were counted in Adobe Photoshop software, using the pencil tool with a SOpixel contrasting yellow circle to mark each colony. As wi th all assays, error bars represent 95% confidence intervals.
experimental system appears more sensitive than the AlamarBlue, which shows basically no effect in a straightforward plaque toxicity assay ( Figure 18 ).
Our fmal experiment was a test for plaque toxicity, using type III homogenates
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>. confluence for a 24-well plate. Wells were close to SO% confluence at the time the cells were exposed, and as the ethanol group shows, they were sufficiently resistant at this density. Sill of a 7Smg/ml homogenate was added to SOOIlI medium in the plaque group and Smcl ethanol for that group. Cells were exposed for 4 hours, treated with Alamarblue, then read 4h after that.
These are the most optimal conditions we arrived at, judging from all of our previous experiments. The error bars outweigh the decreased viability, which is very slight to begin with. While not very exciting, this is consistent with the experiments completed up to this point. It seems like we have never been able to get decent toxicity out of the atherosclerotic material from carotid endarterectomies, and the very first experiments we did with more dilute samples were not much better.
Overall, our impression is that with these experimental models, toxicity is so slight it gets buried in the noise with even the most doggedly consistent handling, unless incredibly low seeding densities are used, at which point we have problems with vehicle and MPG toxicity.
DISCUSSION
Prospects of This Approach
After more than 10 experiments with this experimental system, its drawbacks are obvious; there is a very fine line between vehicle toxicity and overgrown plates, giving a very narrow (less than 48 hours) window of opportunity for experimentation. Therefore the prospects of this approach appear somewhat limited. This appears to be a mainly problem with the sample preparation, however. Variation in the samples procured, together with changes in composition due to handling seem to outweigh the toxic effects seen when oxidized lipids hit the plaque. The clonogenic assay seemed the most free from experimental artifacts, and was apparently exquisitely sensitive to even the slightest levels of growth stimulation and toxicity. Also, using extreme numbers of replicates, as in our most successful experiment ( Figure 13 ) enables slight effects to stand out from the noise. Regardless, a new source of atheroma material is obviously necessary. In previous successful experiments 46 , 1.5g samples of purely soft plaque gruel were obtainable. Such a source would apparently be necessary in order for such experiments to succeed as they have done in the past, or better yet, artificially oxidized lipids. Wang et 
Complimentary Approaches
CONCLUSION
While our hypothesis remains somewhat in question, there have been some indications that MPG may be protective ( Figure 13 ). Also there are obvious toxicity issues, depending on seeding density of the macrophages (Figures 14 and 15) , so it by no means represents the quintessential aldehyde-quenching drug. Despite the shortcomings of this experimental approach however, the overall concept of using antioxidant and carbonyl-quenching therapy to treat atherosclerosis is on solid ground, and is still an active area ofresearch. 47 Combination treatment with other therapies appears to be especially beneficial, both in regards to antioxidant therapi . Thus, it seems that finding an effective aldehyde-quenching agent for additional combined treatment of atherosclerosis 45 ,46 would go a long way towards the elimination of heart disease as the leading cause of death in developed countries.
